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Abstract: FUS1 is a novel tumor suppressor gene identified in the
human chromosome 3p21.3 region where allele losses and ge-
netic alterations occur early and frequently for many human
cancers. Expression of FUS1 protein is absent or reduced in the
majority of lung cancers and premalignant lung lesions. Resto-
ration of wt-FUS1 function in 3p21.3-deficient non-small cell
lung carcinoma cells significantly inhibits tumor cell growth by
induction of apoptosis and alteration of cell cycle kinetics. Here
we present recent findings indicating that FUS1 induces apopto-
sis through the activation of the intrinsic mitochondrial-depen-
dent and Apaf-1-associated pathways and inhibits the function of
protein tyrosine kinases including EGFR, PDGFR, AKT, c-Abl,
and c-Kit. Intravenous administration of a nanoparticle encapsu-
lated FUS1 expression plasmid effectively delivers FUS1 to
distant tumor sites and mediates an antitumor effect in orthotopic
human lung cancer xenograft models. This approach is the
rationale for an ongoing FUS1-nanoparticle-mediated gene de-
livery clinical trial for the treatment of lung cancer.
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Cytogenetic and allelotyping studies of fresh tumors andtumor cell lines have shown that allele losses and genetic
alterations on the short arm of chromosome 3p (3p25, 3p21–
22, 3p14, and 3p12–13) are among the most frequent and
earliest genomic abnormalities involved in a wide spectrum
of human cancers, including lung1–6 and breast.7–9 Multiple
overlapping homozygous deletions have also been found in
the 3p21.3 region, spanning a 120 kb genomic locus in human
lung and breast cancer cell lines.10,11 Chromosomal abnor-
malities in the 3p21.3 region have been frequently detected in
smoke-damaged respiratory epithelium and preneoplastic le-
sions.10,12–13 These findings suggest that one or more putative
3p21.3 tumor suppressor genes function as “gatekeepers” in
the molecular pathogenesis of lung and other human can-
cers.10,12,14 The novel FUS1 gene is one of the nine candidate
TSGs (CACNA2D2, PL6, 101F6, FUS1, BLU, RASSF1,
NPRL2, HYAL2, and HYAL1) that were identified in this
region.1,14–17 In this review, we will describe a pathway
involved in FUS1-mediated tumor suppression and discuss
potential translational applications of the FUS1 TSG for
human lung cancer therapy.
Inactivation of FUS1 In Lung Cancer
Pathogenesis
The FUS1 gene may be inactivated in human cancer
cell lines and primary tumors by haploinsufficiency.16,17 Al-
though single allele loss is common, only a few missense
mutations and C-terminal deletion mutations have been iden-
tified in primary lung cancer samples, and there is no evi-
dence for promoter hypermethylation.6,16,17 FUS1 mRNA
transcripts could be detected on Northern blots of RNAs
prepared from some lung cancer cell lines, but no endogenous
FUS1 protein could be detected in a majority of non-small
cell lung carcinoma (NSCLC) cells and almost all of the
small-cell lung cancer (SCLC) cell lines tested.6,16,17 Myris-
toylation of the FUS1 N-terminus is required for tumor
suppressor activity.17 A loss of expression coupled with a
myristoylation defect of the FUS1 protein was detected in
primary lung cancers. The myristoylation defective FUS1
protein has a greatly reduced half-life and is subject to rapid
proteosomal degradation.17 Using a tissue microarray of 303
lung cancers, loss or reduction of FUS1 expression was
detected in 100% of SCLCs and 82% of NSCLCs.18 In
NSCLCs, loss or reduction of FUS1 expression was associ-
ated with significantly worse overall patient survival.
Squamous metaplasia and dysplasia expressed signifi-
cantly lower levels of FUS1 than did normal and hyper-
plastic bronchial epithelia. Lee et al.19 showed the trans-
lation of FUS1 was significantly down-regulated by
microRNA-378 targeting the 3UTR of FUS1 mRNA and
the ectopic expression of miR-378 enhanced cell survival,
tumor growth, and angiogenesis. A genetically engineered
mouse with a targeted disruption of the FUS1 gene devel-
oped signs of autoimmune disease, showed an increased
frequency of spontaneous vascular tumor formation, and
had defects in natural killer cell maturation coupled with
IL-15 insufficiency.20 These findings suggest that loss of
FUS1 expression may play an important role in the early
pathogenesis of lung cancer.
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The Role of FUS1 in the Intrinsic Apoptotic
Signaling Pathway
We previously used recombinant adenoviruses or N-[1-
(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chlo-
ride/cholesterol nanoparticle-complexed plasmid vectors to
introduce FUS1 and other genes into lung cancer
cells.14,15,17,21,22 FUS1 showed the most potent proapoptotic
activity in human lung cancer cells among these candidate
3p21.3 TSGs.15–17,23 To identify the pathway involved in
FUS1-mediated apoptosis, we used a ProteinChip array-
based SELDI-MS spectrometry to analyze all of the protein
species in complexes immunoprecipitated by anti-FUS1-an-
tibodies. The apoptotic protease-activating factor 1 (Apaf-1)
was identified as a potential cellular target of FUS1 protein by
its direct protein–protein interaction (Figure 1). A computer-
based analysis of the functional domains and signaling motifs
within the amino acid sequence of FUS1 and Apaf-1 proteins
reveals Class II and Class I PDZ24,25 protein–protein interac-
tion motifs at the C-termini of FUS1 and Apaf-1 proteins,
respectively, providing a structural bases for FUS1-Apaf-1
protein–protein interaction. Apaf-1 plays an important role in
the mitochondria-dependent apoptotic pathway.26–28 A rela-
tively high level of endogenous Apaf-1 protein was univer-
sally detected in lung cancer cells. These Apaf-1 proteins
appeared to be functionally inactive, as indicated by their lack
of intrinsic ATPase activity, which is essential for Apaf-1-
mediated caspase activation and apoptosis induction in both
cancer cells deficient in FUS1 expression and in normal cells
with low level of endogenous FUS1 expression.28,29 We
showed that activation of endogenous FUS1 in normal cells
in response to stress, such as UV irradiation, and the forced
expression of FUS1 in FUS1-deficient tumor cells can trigger
cytochrome C release from mitochondria into the cytosol and
cause FUS1 binding to Apaf-1 and recruit it to critical cellular
locations, thus, activating Apaf-1 in situ, initiating Apaf-1-
mediated caspase activation, and inducing apoptosis.17,30,31
Although our proposed mechanism remains to be validated
by identifying all of the components in this complicated
apoptotic apparatus and their dynamic interactions, our find-
ings support a role for loss of FUS1 expression as a critical
event in lung cancer pathogenesis.
Inhibition of Tyrosine Kinase Signaling
by FUS1
We found that reactivating FUS1 in 3p21.3-deficient
lung cancer cells inhibited their growth and induced apopto-
sis, in part, by inhibiting protein tryrosine kinases (PTKs)
such as EGFR, PDGFR, c-Abl, c-Kit, and AKT (Figure 1). A
FIGURE 1. Schema of the FUS1 pathway. Activation of FUS1 in normal cells in response to apoptotic stimuli, stress, or resto-
ration of wt-FUS1 function by ectopic gene transfer in FUS1-deficient tumor cells activates the intrinsic mitochondrial apopto-
sis pathway. Activation of FUS1 triggers cytochrome c (Cyt C) release from the inner membrane of mitochondria to the cy-
tosol, selectively and directly interacts with Apaf-1 and recruits it to a critical subcellular location, and activates Apaf-1 by
induction of its ATPase activity in situ thus facilitating downstream Apaf-1-mediated apoptosome assembly, caspase activation,
and apoptosis induction. Activation of FUS1 may also block MDM2-associated proteolytic degradation of p53 and enhance
the p53-dependent apoptotic pathway. The potent tumor suppressor activity of FUS1 is also in part mediated by its inhibition
of multiple oncogenic protein tyrosine kinases (PTKs) including EGFR, PDGFR, c-Abl, c-Kit, and AKT that are up-regulated in
cancer cells. FUS1-mediated inactivation of these oncogenic PTKs leads to induction of apoptosis and inhibition of tumor cell
proliferation and survival.
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computer-based homology modeling of the FUS1 protein
sequence and structure32 predicts a potential protein kinase A
activation site, and an A kinase anchoring protein homology
motif.17 It has been shown that a FUS1 peptide derived from
FUS1 protein sequence in a region that was deleted in a
mutant FUS1 gene detected in some lung cancer cell lines
inhibits a constitutively active recombinant c-Abl tyrosine
kinase and the full length c-Abl kinase in vitro.33 Platelet-
derived growth factors (PDGFs) play a crucial role in cell
migration, proliferation, apoptosis, and cell survival. Forced
expression of wt-FUS1 by nanoparticle-mediated gene trans-
fer in the PDGFR-expressing SCLC H69 and H417 cell
lines inactivated PDGFR and its downstream targets, PI3K
and AKT kinases, as shown by marked reduction in PTK
phosphorylation.
We explored the ability of FUS1 expression to over-
come gefitinib resistance in NSCLC cells. We found that
reexpression of wt-FUS1 by FUS1-nanoparticle-mediated
gene transfer into FUS1-deficient and gefitinib-resistant
NSCLC cell lines that have wt-EGFR sensitized them to
gefitinib treatment and synergistically induced apoptosis.
FUS1 nanoparticle treatment alone or with gefitinib in ge-
fitinib-resistant NSCLC cells markedly inactivated EGFR and
AKT, as shown by decreased phosphorylation levels of these
proteins, and activated caspase-3, caspase-9, and PARP, as
shown by the increased cleavage of their precursor proteins
on Western blots. Together, these results suggest that com-
bination treatment with FUS1 and PTK inhibitors may be a
useful therapeutic strategy for human lung cancer.
Translational Applications of FUS1 for Lung
Cancer Therapy
We initiated a dose escalation Phase I clinical trial of
FUS1-nanoparticles in patients with chemotherapy refractory
stage IV lung cancer. In this clinical trial, a FUS1 expression
plasmid in a nanoparticle is injected intravenously in stage IV
lung cancer patients who had progressed after cisplatin com-
bination chemotherapy. The trial continues to accrue patients.
We have also explored the combined effects of the
FUS1-nanoparticles with conventional chemotherapy and ex-
ternal beam radiotherapy.31 Forced expression by FUS1-
nanoparticle-mediated gene transfer sensitized NSCLC cells
to cisplatin or -radiation, resulting in a 3- to 8-fold increase
in inhibition of tumor cell viability and induction of apoptosis
in FUS1-transfected cells. Systemic treatment with a combi-
nation of FUS1 nanoparticles and cisplatin in a human lung
cancer orthotopic mouse model synergistically enhanced the
therapeutic efficacy of cisplatin.
We evaluated the combined effects of FUS1 and the
TSG p53 on tumor cell growth and apoptosis induction in
NSCLC cells cotransfected with FUS1- and p53.30 We found
that coexpression of wt-p53 with wt-FUS1, but not the
myristoylation mutant (mt-FUS1), synergistically inhibited
cell proliferation and induced apoptosis in human NSCLC
cells. We also found that coexpression of FUS1 and p53
enhanced the sensitivity of NSCLC cells to treatments with
the DNA-damaging agents -radiation and cisplatin. We
found that the observed synergistic tumor suppression by
FUS1 and p53 correlated with FUS1-mediated down-regula-
tion of MDM2 expression resulting in the accumulation and
stabilization of p53 protein and the up-regulation of Apaf-1
expression with activation of the caspase cascade (Figure 1).
Our results demonstrate an important role for FUS1 in mod-
ulating chemo- and radiosensitivities of lung cancer cells and
suggest that an optimal combination of molecular therapeu-
tics, such as the proapoptotic tumor suppressor FUS1-nano-
particle and conventional anticancer agents, such as cisplatin,
may be an effective treatment strategy for human lung cancer.
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